Precision oncology company 4baseCare has raised $10 million (around ₹90 crore) in the first close of its Series B funding round, co-led by investors Ashish Kacholia and Lashit Sanghvi, the company announced in a LinkedIn post.
The fresh capital will be deployed to scale 4baseCare’s clinico-genomic platforms, expand global collaborations, and accelerate the generation of population-relevant real-world evidence to improve cancer care outcomes across geographies.
Founded with a focus on inclusive precision oncology, 4baseCare uses genomics and artificial intelligence to deliver cancer insights tailored to specific populations. The company highlighted that cancer behaviour and treatment response vary across regions, making population-relevant data critical for effective care delivery.
“With this milestone, we aim to deepen our AI-driven cancer intelligence and strengthen evidence that represents diverse and under-served populations,” the company said.
The Series B funding marks a key step in 4baseCare’s effort to make precise, data-driven cancer care more accessible and equitable globally.